


IN THE CLAIMS

1. (presently amended) The method for treating nonallergic rhinitis in a patient comprising administering a therapeutically effective amount of a use of compounds components of the general formula (I)



~~in which~~ wherein

R¹ is -C₁-C₆-alkyl, straight-chain or branched-chain, saturated or partially unsaturated, where appropriate substituted one or more times by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles having 3-14 ring members or mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles having 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S, where the carbocyclic and heterocyclic substituents in turn may be substituted where appropriate one or more times by -OH, -SH, -NH₂, -NHC₁-C₆-alkyl, -N(C₁-C₆-alkyl)₂, -NHC₆-C₁₄-aryl, -N(C₆-C₁₄-aryl)₂, -N(C₁-C₆-alkyl)(C₆-C₁₄-aryl), -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁-C₆-alkyl, -O-C₆-C₁₄-aryl, -C₁-C₆-alkyl, -C₆-C₁₄-aryl or/and -COOH,

where each C₁-C₆-alkyl radical on the carbocyclic and heterocyclic substituents may itself be substituted one or more times by -F, -Cl, -Br, -I, -OH or/and C₆-C₁₄-aryl, and where each C₆-C₁₄-aryl radical on the carbocyclic and heterocyclic substituents may itself be substituted one or more times by -F, -Cl, -Br, -I, -OH or/and C₁-C₆-alkyl,

R^2 , R^3 may be hydrogen or -OH, it being necessary for at least one of the two substituents to be -OH;

R^4 is a mono- or polycyclic aromatic carbocycle having 6-14 ring members or a mono- or polycyclic heterocycle having 5-15 ring members, where the heteroatoms are selected from N, O and S,

where appropriate substituted one or more times by -F, -Cl, -Br, -I, -OH, -SH, -NH₂, -NH(C₁-C₆-alkyl), -N(C₁-C₆-alkyl)₂, -NH(C₆-C₁₄-aryl), -N(C₆-C₁₄-aryl)₂, -N(C₁-C₆-alkyl)(C₆-C₁₄-aryl), -NO₂, -CN, -O-C₁-C₆-alkyl, -O-C₆-C₁₄-aryl, -C₁-C₆-alkyl, -C₆-C₁₄-aryl or/and -COOH,

where each C₁-C₆-alkyl radical ~~may itself be~~ is optionally substituted ~~one or more times by~~ at least once with -F, -Cl, -Br, -I, -OH, ~~or/and~~ -C₆-C₁₄-aryl, and wherein each C₆-C₁₄-aryl radical ~~may itself be~~ is optionally substituted ~~one or more times by~~ at least once with -F, -Cl, -Br, -I, -OH ~~or/and~~ and C₁-C₆-alkyl, ~~for the treatment of nonallergic rhinitis~~ to a patient in need thereof.

2. (presently amended) ~~The use as claimed in~~ the method of claim 1,

~~characterized in that~~ wherein

~~the said compounds~~ compound are is selected from the group consisting of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide (AWD 12-281), N-(3,5-dichloropyrid-4-yl)-2-[5-hydroxy-1-(4-hydroxybenzyl)-1H-indol-3-yl]glyoxylamide (AWD 12-322) and N-(3,5-dichloropyrid-4-yl)-[1-(2,6-difluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide semi-ethyl acetate (AWD 12-298) ~~or~~ the and pharmacologically acceptable salts thereof.

3. (presently amended) ~~The use as claimed in~~ method of claim 1, ~~or 2,~~
wherein

~~characterized in that~~

the nonallergic rhinitis is selected from vasomotor rhinitis, nonallergic rhinitis with eosinophils syndrome, chronic sinusitis and rhinitis medicamentosa.

4. (presently amended) The ~~use as claimed in~~ method of claim 1, or 2 wherein,

~~characterized in that~~

the rhinitis ~~caused by infection~~ is a symptom, ~~not caused by allergy, or~~ caused by infection with at least one of a viral, or bacterial, infection or of an infection with fungi fungal or parasites or of a combination of the germs mentioned, parasitic infection and the rhinitis is selected from the group consisting of vasomotor rhinitis, nonallergic rhinitis with eosinophils syndrome, chronic sinusitis and rhinitis medicamentosa.